Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citadel 205 phase 2 study of INCB050465 in relapsed or refractory mantle cell lymphoma
MOH_2019-01-12_004843Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of parsaclisib in mantle cell lymphoma (MCL) (2 arms), sponsored by Incyte. Primary endpoint: Efficacy of INCB050465. Started Oct 2018; status: active, not recruiting.
02
Drugs
parsaclisib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on MOH_2019-01-12_004843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-12_004843.